MedTrace Logo

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

NCT01193608 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2017-02-23

Study results available
· View outcomes & findings →

Summary

This is a study to evaluate the safety of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients will receive either AAB-003 (PF-05236812) or placebo. Each patient's participation will last approximately 41 weeks.

Conditions

Interventions

DRUG

AAB-003 (PF-05236812)

0.5 mg/kg AAB-003, IV

DRUG

AAB-003 (PF-05236812)

1 mg/kg AAB-003, IV

DRUG

AAB-003 (PF-05236812)

2 mg/kg AAB-003, IV

DRUG

AAB-003 (PF-05236812)

4 mg/kg AAB-003, IV

DRUG

AAB-003 (PF-05236812)

8 mg/kg AAB-003, IV

OTHER

Placebo

Placebo, IV

Sponsors & Collaborators

  • JANSSEN Alzheimer Immunotherapy Research & Development, LLC

    collaborator INDUSTRY

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE

Eligibility

Min Age
50 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • United States
  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01193608 on ClinicalTrials.gov